These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 25468385)

  • 1. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.
    Limdi NA; Nolin TD; Booth SL; Centi A; Marques MB; Crowley MR; Allon M; Beasley TM
    Am J Kidney Dis; 2015 May; 65(5):701-9. PubMed ID: 25468385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department.
    Anthony CJ; Karim S; Ackroyd-Stolarz S; Fry A; Murphy NG; Christie R; Zed PJ
    Ann Pharmacother; 2011 Jul; 45(7-8):881-7. PubMed ID: 21750309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
    Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
    Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating warfarin management by pharmacists in a community teaching hospital.
    Chilipko AA; Norwood DK
    Consult Pharm; 2014 Feb; 29(2):95-103. PubMed ID: 24513419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [INTERNATIONAL NORMALIZED RATIO VALUES AND HEMORRHAGE IN HOSPITALIZED PATIENTS STARTING WARFARIN THERPY: AN OBSERVATIONAL STUDY].
    Abadi U; Ellis MH
    Harefuah; 2015 Aug; 154(8):490-3, 541-2. PubMed ID: 26480611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.
    Yanik MV; Irvin MR; Beasley TM; Jacobson PA; Julian BA; Limdi NA
    Pharmacotherapy; 2017 Nov; 37(11):1366-1373. PubMed ID: 28949423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.
    Hylek EM; Chang YC; Skates SJ; Hughes RA; Singer DE
    Arch Intern Med; 2000 Jun; 160(11):1612-7. PubMed ID: 10847254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry.
    Subherwal S; Peterson ED; Chen AY; Roe MT; Washam JB; Gage BF; Bach RG; Bhatt DL; Wiviott SD; Lopes RD; Alexander KP; Wang TY
    Circulation; 2012 Mar; 125(11):1414-23. PubMed ID: 22319105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Over-Anticoagulation in Warfarin Users in the UK General Population: A Nested Case-Control Study in a Primary Health Care Database.
    Martín-Pérez M; Gaist D; de Abajo FJ; García Rodríguez LA
    Thromb Haemost; 2019 Jan; 119(1):66-76. PubMed ID: 30597501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
    Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of hemorrhage among patients with warfarin-associated coagulopathy.
    Garcia DA; Regan S; Crowther M; Hylek EM
    J Am Coll Cardiol; 2006 Feb; 47(4):804-8. PubMed ID: 16487849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle.
    Kucher N; Connolly S; Beckman JA; Cheng LH; Tsilimingras KV; Fanikos J; Goldhaber SZ
    Arch Intern Med; 2004 Oct; 164(19):2176-9. PubMed ID: 15505133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
    Xian Y; Liang L; Smith EE; Schwamm LH; Reeves MJ; Olson DM; Hernandez AF; Fonarow GC; Peterson ED
    JAMA; 2012 Jun; 307(24):2600-8. PubMed ID: 22735429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function.
    Hirai T; Hamada Y; Geka Y; Kuwana S; Hirai K; Ishibashi M; Fukaya Y; Kimura T
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1491-1497. PubMed ID: 28795244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemorrhagic events lead to an increase in international normalized ratio in patients on warfarin.
    Perona S; Ford M; Rindone J
    J Pharm Pract; 2011 Oct; 24(5):494-7. PubMed ID: 22156711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.
    Fang MC; Chang Y; Hylek EM; Rosand J; Greenberg SM; Go AS; Singer DE
    Ann Intern Med; 2004 Nov; 141(10):745-52. PubMed ID: 15545674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
    Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
    J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
    Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin.
    Dager WE; King JH; Regalia RC; Williamson D; Gosselin RC; White RH; Tharratt RS; Albertson TE
    Pharmacotherapy; 2006 Aug; 26(8):1091-8. PubMed ID: 16863486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting.
    Tsu LV; Dienes JE; Dager WE
    Ann Pharmacother; 2012 Dec; 46(12):1617-26. PubMed ID: 23249867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.